Improving nutritional status after allogeneic stem cell transplantation: results of phase 2 ALLONUT clinical trial

被引:1
|
作者
Estran, Sophie [1 ]
Loschi, Michael [1 ,2 ]
Benachour, Sami [1 ]
Soldati, Alizee [1 ]
Chiche, Edmond [1 ]
Sammut, Rinzine [1 ]
Robert, Guillaume [2 ]
Jacquel, Arnaud [2 ]
Chibois, Jacques [3 ]
Schneider, Stephane [4 ]
Cluzeau, Thomas [1 ,2 ]
机构
[1] Cote dAzur Univ, Nice Univ Hosp, Hematol Dept, Nice, France
[2] Mediterranean Ctr Mol Med, INSERM U1065, Nice, France
[3] Bastide St Antoine, Grasse, France
[4] Cote dAzur Univ, Nice Univ Hosp, Nutr Dept, Nice, France
关键词
QUALITY-OF-LIFE; CYCLOPHOSPHAMIDE; GUIDELINES; THERAPY; DISEASE;
D O I
10.1038/s41409-024-02271-w
中图分类号
Q6 [生物物理学];
学科分类号
071011 ;
摘要
Malnutrition increases the risk of non-relapse mortality after allogeneic stem cell transplantation (aHSCT). Here are the results of the ALLONUT clinical trial designed to improve the nutritional outcome of patients receiving aHSCT. ALLONUT is a prospective open label phase 2 clinical trial assessing the efficacy of a close tailored nutritional support and management with traditional and original solutions to improve patients nutritional status following aHSCT. Nutritional status evaluation was performed before transplantation, on Day 0, 30, 100 and one year after transplantation. The study involved 70 patients treated by aHSCT. 10% of patients were moderately or severely malnutrition at baseline and 26.9 were severely malnutrition at D30. Patients' nutritional status improved thanks to the cooking classes and the personalized outpatient nutrition program. At D100, 23% were still malnutrition, while only 10.8% were severely malnutrition one year after transplantation. The QLQ-C30 show that quality of life (QoL) decreased until D30, and improve to reach the pre-transplant level on D100 before exceeding it on D360. The study confirmed that a close, personalized nutritional program combining traditional and original measures can improve both nutritional status and QoL for patients suffering from moderate or severe malnutrition after aHCST.
引用
收藏
页码:957 / 964
页数:8
相关论文
共 50 条
  • [21] Cataract after allogeneic hematopoietic stem cell transplantation inchildhood
    Fahnehjelm, Kristina Tear
    Tornquist, Alba Lucia
    Olsson, Monica
    Backstrom, Ingrid
    Gronlund, Marita Andersson
    Winiarski, Jacek
    ACTA PAEDIATRICA, 2016, 105 (01) : 82 - 89
  • [22] Monitoring of cytomegalovirus infection after allogeneic stem cell transplantation
    Kuljic-Kapulica, Nada
    Stamatovic, Dragana
    Savic, Dejana
    Jovanovic, Dragutin
    Tukic, Ljiljana
    Andjelkovic, Nebojsa
    VOJNOSANITETSKI PREGLED, 2010, 67 (05) : 375 - 378
  • [23] A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis
    Lunetta, Christian
    Lizio, Andrea
    Cabona, Corrado
    Gerardi, Francesca
    Sansone, Valeria Ada
    Corbo, Massimo
    Scialo, Carlo
    Angelucci, Emanuele
    Gualandi, Francesca
    Marenco, Paola
    Grillo, Giovanni
    Cairoli, Roberto
    Cesana, Clara
    Saccardi, Riccardo
    Melazzini, Mario Giovanni
    Mancardi, Gianluigi
    Caponnetto, Claudia
    JOURNAL OF NEUROLOGY, 2022, 269 (10) : 5337 - 5346
  • [24] Heart failure after allogeneic hematopoietic stem cell transplantation
    Mo, Xiao-Dong
    Xu, Lan-Ping
    Liu, Dai-Hong
    Zhang, Xiao-Hui
    Chen, Huan
    Chen, Yu-Hong
    Han, Wei
    Wang, Yu
    Wang, Feng-Rong
    Wang, Jing-Zhi
    Zhao, Ting
    Yan, Chen-Hua
    Sun, Yu-Qian
    Liu, Kai-Yan
    Huang, Xiao-Jun
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 167 (06) : 2502 - 2506
  • [25] The use of ibrutinib before and after allogeneic stem cell transplantation
    Martino, Massimo
    Ferreri, Anna
    Naso, Virginia
    Moscato, Tiziana
    Loteta, Barbara
    Gentile, Massimo
    Morabito, Antonella
    Provenzano, Fabio
    Cimminiello, Michele
    Carella, Angelo Michele, Jr.
    Console, Giuseppe
    Recchia, Anna Grazia
    EXPERT OPINION ON ORPHAN DRUGS, 2019, 7 (04): : 171 - 180
  • [26] Complications after allogeneic bone marrow and stem cell transplantation
    Wollmer, E.
    Neubauer, A.
    INTERNIST, 2014, 55 (05): : 547 - 560
  • [27] Results of a phase I/II clinical trial: standardized, non-xenogenic, cultivated limbal stem cell transplantation
    Zakaria, Nadia
    Possemiers, Tine
    Dhubhghaill, Sorcha Ni
    Leysen, Inge
    Rozema, Jos
    Koppen, Carina
    Timmermans, Jean-Pierre
    Berneman, Zwi
    Tassignon, Marie-Jose
    JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
  • [28] Complications after allogeneic bone marrow and stem cell transplantation
    Wollmer, E.
    Neubauer, A.
    INTERNIST, 2014, 55 (05): : 547 - 560
  • [29] Bullous pemphigoid after allogeneic hematopoietic stem cell transplantation
    Kato, Keisuke
    Koike, Kazutoshi
    Kobayashi, Chie
    Iijima, Shigeruko
    Hashimoto, Takashi
    Tsuchida, Masahiro
    PEDIATRICS INTERNATIONAL, 2015, 57 (03) : 480 - 483
  • [30] Update on Stem Cell Transplantation for Systemic Sclerosis: Recent Trial Results
    Naraghi, Kamran
    van Laar, Jacob M.
    CURRENT RHEUMATOLOGY REPORTS, 2013, 15 (05)